The evolving role and utility of off-label drug use in multiple myeloma
The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active classes. The advances seen in MM therapy have rel...
Saved in:
Main Authors: | James H Stoeckle (Author), Faith E Davies (Author), Louis Williams (Author), Eileen M Boyle (Author), Gareth J Morgan (Author) |
---|---|
Format: | Book |
Published: |
Open Exploration Publishing Inc.,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021) -
Off-label drug in the newborn
by: Laura Cuzzolin
Published: (2014) -
Drug utilization in neonatal setting of Pakistan: focus on unlicensed and off label drug prescribing
by: Muhammad Aamir, et al.
Published: (2018) -
Off-label prescription of drugs at hospital
by: Vicente Arocas Casañ, et al.
Published: (2016) -
Off-label and unlicensed drugs in neonatology
by: Segundo Rite-Gracia, et al.
Published: (2021)